Ann: Osteopore strikes collaboration with NASDAQ-listed CytoMed, page-4

Its another tie in under the very strong Government umbrella support for its bio-tech ambitions for Singapore, that have been 20 years in the making now:

"SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including blood and solid cancers has obtained full approval for its first-in-human Phase I clinical trial (“ANGELICA Trial”) using its patented allogeneic chimeric antigen receptor T cell (“CAR-T cell”) against several blood and solid tumors in collaboration with the National University Hospital (“NUH”) of Singapore. The ANGELICA Trial is co-supported by the Singapore Ministry of Health through the National Medical Research Council (“NMRC”) Office, and MOH Holdings Pte Ltd under the NMRC Clinical Trial Grant Industry Collaborative Trials (CTG-ICT) scheme (MOH-001646). Grant details are confidential."

OSX is very much on the endorsed listed of Singapore authorities (SingHealth and A*Star) and is collaborating with companies that also are. Don't get how the share price is going backwards on this stuff. There is very likely financial support in the wings, as there was for CytoMed.